🎉 M&A multiples are live!
Check it out!

Contineum Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Contineum Therapeutics and other public comps.

See Contineum Therapeutics Valuation Multiples

Contineum Therapeutics Overview

About Contineum Therapeutics

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.


Founded

2009

HQ

United States of America
Employees

31

Financials

LTM Revenue $0.8M

LTM EBITDA -$48.1M

EV

$3.5M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Contineum Therapeutics Financials

Contineum Therapeutics has a last 12-month revenue of $0.8M and a last 12-month EBITDA of -$48.1M.

In the most recent fiscal year, Contineum Therapeutics achieved revenue of $50.0M and an EBITDA of $23.6M.

Contineum Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Contineum Therapeutics valuation multiples based on analyst estimates

Contineum Therapeutics P&L

FY 2022 FY 2023 FY 2024 LTM NTM
Revenue n/a $50.0M n/a $0.8M XXX
Gross Profit n/a n/a n/a XXX XXX
Gross Margin NaN% NaN% NaN% XXX XXX
EBITDA -$23.5M $23.6M -$46.4M -$48.1M XXX
EBITDA Margin -Infinity% 47% -Infinity% -6022% XXX
Net Profit -$29.0M -$24.3M $22.7M XXX XXX
Net Margin -Infinity% -49% Infinity% XXX XXX
Net Debt $0.3M n/a n/a XXX XXX

Financial data powered by Morningstar, Inc.

Contineum Therapeutics Stock Performance

As of February 7, 2025, Contineum Therapeutics's stock price is $8.

Contineum Therapeutics has current market cap of $217M, and EV of $3.5M.

See Contineum Therapeutics trading valuation data

Contineum Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$3.5M $217M XXX XXX XXX XXX $-1.90

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Contineum Therapeutics Valuation Multiples

As of February 7, 2025, Contineum Therapeutics has market cap of $217M and EV of $3.5M.

Contineum Therapeutics's trades at 4.4x LTM EV/Revenue multiple, and -0.1x LTM EBITDA.

Analysts estimate Contineum Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Contineum Therapeutics and 10K+ public comps

Contineum Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $3.5M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -0.1x XXX XXX XXX
P/E -5.6x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Contineum Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Contineum Therapeutics Valuation Multiples

Contineum Therapeutics's NTM/LTM revenue growth is 738%

Contineum Therapeutics's revenue per employee for the last fiscal year averaged $1.6M, while opex per employee averaged $1.1M for the same period.

Over next 12 months, Contineum Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Contineum Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Contineum Therapeutics and other 10K+ public comps

Contineum Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -100% XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth -297% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee $1.6M XXX XXX XXX XXX
Opex per Employee $1.1M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 13% XXX XXX XXX XXX
R&D Expenses to Revenue 55% XXX XXX XXX XXX
Opex to Revenue 68% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Medical Devices
Consumer SaaS
Streaming Platforms
AdTech Software
Climate Tech
GRC Software
Developer Tools

Contineum Therapeutics Public Comps

See valuation multiples for Contineum Therapeutics public comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Contineum Therapeutics M&A and Investment Activity

Contineum Therapeutics acquired  XXX companies to date.

Last acquisition by Contineum Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Contineum Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Contineum Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Contineum Therapeutics

When was Contineum Therapeutics founded? Contineum Therapeutics was founded in 2009.
Where is Contineum Therapeutics headquartered? Contineum Therapeutics is headquartered in United States of America.
How many employees does Contineum Therapeutics have? As of today, Contineum Therapeutics has 31 employees.
Who is the CEO of Contineum Therapeutics? Contineum Therapeutics's CEO is Mr. Carmine Stengone.
Is Contineum Therapeutics publicy listed? Yes, Contineum Therapeutics is a public company listed on NAS.
What is the stock symbol of Contineum Therapeutics? Contineum Therapeutics trades under CTNM ticker.
When did Contineum Therapeutics go public? Contineum Therapeutics went public in 2024.
Who are competitors of Contineum Therapeutics? Similar companies to Contineum Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Contineum Therapeutics? Contineum Therapeutics's current market cap is $217M
What is the current revenue of Contineum Therapeutics? Contineum Therapeutics's last 12-month revenue is $0.8M.
What is the current EBITDA of Contineum Therapeutics? Contineum Therapeutics's last 12-month EBITDA is -$48.1M.
What is the current EV/Revenue multiple of Contineum Therapeutics? Current revenue multiple of Contineum Therapeutics is 4.4x.
What is the current EV/EBITDA multiple of Contineum Therapeutics? Current EBITDA multiple of Contineum Therapeutics is -0.1x.
Is Contineum Therapeutics profitable? Yes, Contineum Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.